title: Infarct size-reducing effect of heat stress and alpha1 adrenoceptors in rats.
abstract: 1. Noradrenaline (NA), which is abundantly released during heat stress (HS), is known to induce both delayed cardioprotection and heat stress protein (HSP) 72 expression by the mediation of alpha, adrenoceptors. Therefore, we have investigated the implication of alpha1 adrenoceptors in HS-induced resistance to myocardial infarction, in the isolated rat heart model. 2. Rats were pretreated with prazosin (1 mg kg(-1), i.p., Praz) or 5-methylurapidil (3 mg kg(-1), i.v., 5MU) or chloroethylclonidine (3 mg kg(-1), i.v., CEC) or vehicle (V) in order to selectively antagonize alpha1, alpha1A and alpha1B adrenoceptors. They were then either heat stressed (42 degrees C for 15 min) or sham anaesthetized. Twenty-four hours later. their hearts were isolated, retrogradely perfused, and subjected to a 30 min occlusion of the left coronary artery followed by 120 min of reperfusion. 3. Infarct-to-risk ratio was significantly reduced in HS+V (15.4+/-1.8%) compared to Sham+V (35.7+/-1.3%) hearts. This effect was abolished in Praz-treated (29.1+/-1.6% in HS+Praz vs 34.1+/-4.0% in Sham+Praz), 5MU-treated (34.5+/-2.2% in HS+5MU vs 31.2+/-2.0% in Sham+5MU) and CEC-treated (33.4+/-3.0% in HS+CEC vs 32.4+/-1.3% in Sham+CEC) groups. Western blot analysis of myocardial HSP72 showed an HS-induced increase of this protein, which was not modified by Praz, 5MU and CEC pretreatments. 4. We conclude that both alpha1A and alpha1B adrenoceptor subtypes appear to play a role in the heat stress-induced cardioprotection, independently of the HSP72 level. Further investigations are required to elucidate the precise role of HSPs in this adaptative response.
authors.affiliation: Laboratoire de Pharmacologie Cardiovasculaire Expérimentale-Biomolécules, Université Joseph Fourier, La Tronche, France.
authors.forename: M
authors.initials: M
authors.lastname: Joyeux
authors.forename: D
authors.initials: D
authors.lastname: Godin-Ribuot
authors.forename: A
authors.initials: A
authors.lastname: Patel
authors.forename: P
authors.initials: P
authors.lastname: Demenge
authors.forename: D M
authors.initials: DM
authors.lastname: Yellon
authors.forename: C
authors.initials: C
authors.lastname: Ribuot
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D003000:Clonidine / Q000031:analogs & derivatives / Q000494:pharmacology; D050884:HSP72 Heat-Shock Proteins; D018882:Heat Stress Disorders / Q000150:complications*; D006360:Heat-Shock Proteins / Q000032:analysis / Q000378:metabolism*; D007238:Infarction / Q000517:prevention & control*; D008297:Male; D017202:Myocardial Ischemia / Q000517:prevention & control; D009924:Organ Culture Techniques; D010879:Piperazines / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018340:Receptors, Adrenergic, alpha-1 / Q000145:classification / Q000502:physiology*; D015427:Reperfusion Injury
chemical_list: D000317:Adrenergic alpha-Antagonists; D050884:HSP72 Heat-Shock Proteins; D006360:Heat-Shock Proteins; D010879:Piperazines; D018340:Receptors, Adrenergic, alpha-1; C057446:5-methylurapidil; C051731:chlorethylclonidine; D003000:Clonidine; D011224:Prazosin